Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounding with Biotechnology Products, Part 2: Product-specific Considerations

Author(s):  Allen Loyd V Jr

Issue:  Nov/Dec 2022 - Volume 26, Number 6
View All Articles in Issue

Page(s):  446-466

Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 1
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 2
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 3
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 4
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 5
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 6
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 7
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 8
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 9
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 10
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 11
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 12
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 13
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 14
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 15
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 16
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 17
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 18
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 19
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 20
Compounding with Biotechnology Products, Part 2: Product-specific Considerations Page 21

Download in electronic PDF format for $75

Abstract:  Biotechnology drugs involve any technique that uses living organisms in their production or modification. These biotechnology drugs are prepared using different techniques such as recombinant DNA technology monoclonal antibody technologies along with tissue cultures living cells and cell enzymes to make specific products. These new pharmaceuticals are utilized in the diagnosis treatment and prevention of disease, but, because of the risk of clinically important and unusual and potentially harmful adverse effects produced, these agents require increased safety surveillance, and it is very important for pharmacists to participate in any adverse event reporting and monitoring program for these new products. The first biotechnology pharmaceuticals are proteins, but, eventually, an ever-increasing number of smaller molecules may be discovered through the previously mentioned methods and may become a mainstay in new pharmaceutical research and development in producing new drug products. Pharmacists involved in compounding must be aware of not only the biotechnology agent itself but especially of all of the different excipients that are required in order to produce a stable and safe preparation for patient use. Compounding involving these formulations should involve the simplest procedures and formulations as possible, maintaining sterility throughout the entire process. It is important to maintain a drug’s biologic activity up to the point of administration to the patient, and the pharmacist can assist in explaining the various factors involved in storage preparation and administration of the drugs to the patient. In the first part of this two-part series of articles, we discussed the general considerations involved in compounding with biotechnology products. In this final part of the series, we discuss the formulations for a number of commercially available biotechnology products, the purpose of each of the ingredients, and any uniqueness about their formulations.

Related Keywords: Loyd V, Allen, Jr., PhD, RPh, specialty biotechnology products, recombinant DNA technology, monoclonal antibody technology, proteins, polypeptide molecules, peptide technology, formulation composition, stabilizers, excipients, chelating agents, antioxidants, preservatives, polyols, tonicity-adjusting agents, parenteral administration, compounded sterile preparations, biologic activity, filters, sorption, albumin, solubility, chemical instability, physicochemical factors, agitation, quality control, diluents, antisense agents, clotting factors, hematopoietic factors, hormones, interferons, interleukins, HIV, human immunodeficiency virus, lepirudin, anticoagulant agents, fomivirsen sodium, efavirenz, antihemophilic factors, recombinant factor VIII, colony-stimulating factors, granulocyte colony-stimulating factor, filgrastim, pegfilgrastim, monomethoxypolyethylene glycol, PEG, pegylation, sargramostim, granulocyte-macrophage colony-stimulating factor, hemophilia, bleeding disorders, clotting disorders, autologous bone marrow transplantation, erythropoietin, epoetin alfa, hematopoietin, haematopoietin, darbepoietin alfa, drotrecogin alfa, fusion inhibitors, enfuvirtide, growth factors, becaplermin, human growth hormone, hGH, somatotropin, interferon beta-1a, interferon beta-1b, cytokines, aldesleukin, oprelvekin, monoclonal antibodies, anakinra, immunosuppressants, adalimumab, basiliximab, bevacizumab, daclizumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, infliximab, muromonab-CD3, omalizumab, palivizumab, rituximab, satumomab pendetide, tissue plasminogen activators, tocilizumab, trastuzumab, recombinant alteplase, recombinant reteplase, recombinant tenecteplase, vaccines, haemophilus B conjugate vaccine, rasburicase, patient information, patient education, self administration, commercial formulations, storage and handling requirements

Related Categories: EXCIPIENTS, TECHNOLOGY, PATIENT EDUCATION, ADVERSE DRUG EVENTS, ALLERGY/IMMUNOLOGY/INFLAMMATION, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Compounding with Biotechnology Products, Part 1: General Considerations
Allen Loyd V Jr
Sep/Oct 2022
Pg. 385-395

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 1
Allen Loyd V Jr
Jan/Feb 2015
Pg. 38-40

Extemporaneous Topical Minoxidil Solutions for the Treatment of Alopecia: Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base
Spennacchio Antonio
, Lopedota Angela Assunta, Lopalco Antonio, Dibenedetto Maria Teresa, la Forgia Flavia Maria, Fontana Sergio, Franco Massimo, Denora Nunzio
May/Jun 2023
Pg. 256-262

Quality Assurance for Sterile Products
Kastango Eric S
, Douglass Kate
Jul/Aug 2001
Pg. 246-253

Basics of Sterile Compounding: Manipulating Peptides and Proteins
Akers Michael J
May/Jun 2017
Pg. 223-228

Autoclaves for the Sterilization of Compounded Parenteral Products
Rahe Hank
Mar/Apr 2003
Pg. 114-116

How to Handle a Product Recall
Allen Loyd V Jr
Jul/Aug 2003
Pg. 292-293

Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base
Lopalco Antonio
, Lopedota Angela, Aurelio Fiorenza, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Sep/Oct 2021
Pg. 427-430

Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Allen Loyd V Jr
Nov/Dec 2023
Pg. 474-481

Product Containment in the Compounding Laboratory
Vidrine Eric
May/Jun 2003
Pg. 213-214

Sterile Compounding with Barrier-Isolation Technology
Rahe Hank
Jul/Aug 2001
Pg. 254-258

Improving the Management, Operations and Cost Effectiveness of Sterile-Product Compounding
Kastango Eric S
, Douglass Kate
Jul/Aug 1999
Pg. 253-258

Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio
, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
May/Jun 2023
Pg. 250-255

Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio
, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jan/Feb 2023
Pg. 72-77

Technology Spotlight: Electric Mixing Machines
Schneider Gary
May/Jun 2002
Pg. 188

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
Jul/Aug 2015
Pg. 280-287

PreScription: Compounding with Manufactured Products
Allen Loyd V Jr
Nov/Dec 2010
Pg. 448

Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues
Allen Loyd V Jr
Jul/Aug 2021
Pg. 311-317

Return to Top